Medication info
Valsartan and Rosuvastatin Tablets 20/160 mg

Valsartan and Rosuvastatin Tablets 20/160 mg

Prescription medicationTabletOral
Ingredient · strength
Rosuvastatin Calcium›20.8mg / 1 tabletValsartan›160mg / 1 tablet
Manufacturer / importer
Myeongmoon Pharmaceutical Co., Ltd.
Appearance
Brown oval film-coated tablets
Packaging
30 tablets/box[(10 tablets/PTP)*3]
Approval status
Active

MFDS item code 202003856 · Approved 2020.05.26 · Insurance code 649807700

Summary

Main use
Treatment of hypertension and heart failure, improvement of dyslipidemia, and inhibition of atherosclerosis progression and cardiovascular risk
Who takes it
Adults · Children
Adult dose
This medicine is for use in adults only. The dosage should be individualized for each patient based on the efficacy and tolerability of the valsartan and rosuvastatin components. ◆ Valsartan 1. Essential hypertension Take with water during a meal or between meals. If possible, it is recommended to take the medicine at the same time each day (e.g., in the morning). 1) Adults: The recommended dose is 80 mg of valsartan orally once daily, regardless of sex or race. The blood pressure-lowering effect develops gradually within 2 weeks and reaches its maximum after 4 weeks. For patients whose blood pressure is not adequately controlled, the dose may be increased to 160 mg once daily or a diuretic may be administered concomitantly. If additional blood pressure reduction is needed, the dose may be increased to a maximum of 320 mg daily. 2) Older adults (75 years or older): Initiate treatment with 40 mg of this medicine once daily. 3) Patients with renal impairment: (1) Creatinine clearance 20 ∼ 50 mL/min: No dose adjustment is necessary. (2) Creatinine clearance 10 ∼ 20 mL/min: Initiate treatment with 40 mg of this medicine once daily. (3) Creatinine clearance below 10 mL/min and patients on dialysis: Do not administer this medicine. 4) Patients with intravascular volume depletion: For patients with intravascular volume depletion (e.g., patients taking high doses of diuretics whose dose cannot be reduced), initiate treatment with 40 mg of this medicine once daily. 5) Patients with hepatic impairment: In patients with mild or moderate hepatic impairment, initiate treatment with 40 mg of this medicine once daily; the dose should not exceed 80 mg daily. Do not administer this medicine to patients with severe hepatic impairment, cirrhosis, or cholestasis. 2. Heart failure Adults: The recommended initial dose is 40 mg of this medicine orally twice daily. The dose may be increased to 80 mg or 160 mg per dose. When administered concomitantly with a diuretic, consideration should be given to reducing the diuretic dose. The maximum daily dose is 320 mg, administered in divided doses. Triple combination therapy with this medicine, an ACE inhibitor, and a beta blocker is not recommended. 3. Reduction of the risk of death after myocardial infarction Adults: Treatment may be initiated within 12 hours after the onset of myocardial infarction. The recommended initial dose is 20 mg of this medicine twice daily, followed over several weeks by dose increases to 40 mg, 80 mg, and 160 mg per dose twice daily, taking the patient's tolerability into account. Consider dose reduction if symptoms of hypotension or renal failure occur. This medicine may also be administered to patients receiving other treatments after myocardial infarction (e.g., thrombolytic agents, acetylsalicylic acid, beta blockers, and statins). However, concomitant use with an ACE inhibitor is not recommended. 4. Patients with renal impairment: No dose adjustment is necessary when creatinine clearance is 10 mL/min or higher. However, this medicine should not be administered to patients with creatinine clearance below 10 mL/min or to patients on dialysis, as there is no experience with its use in these patients. 5. Patients with hepatic impairment: In patients with mild or moderate hepatic impairment, the daily dose of this medicine should preferably not exceed 80 mg. If administering 80 mg or more daily, consider whether the benefits of dose escalation outweigh the risks. Do not administer this medicine to patients with severe hepatic impairment, cirrhosis, or cholestasis. ◆ Rosuvastatin 1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with this medicine, and continue the diet throughout the treatment period. This medicine may be taken at any time of day, with or without food. The initial dose is 5 milligrams once daily. If a greater reduction in LDL cholesterol is needed, the dose may be adjusted to the maintenance dose. The maintenance dose is 10 milligrams once daily, which is sufficient for most patients. The maintenance dose should be adjusted appropriately at intervals of 4 weeks or longer according to LDL cholesterol levels, treatment goals, and patient response; it may be increased to a maximum of 20 milligrams daily. 2. Older adults: No dose adjustment is necessary. 3. Patients with renal impairment: No dose adjustment is necessary in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Particular caution is required when administering 20 mg of this medicine to patients with moderate renal impairment. 4. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or lower, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score above 9. Do not administer this medicine to patients with active liver disease. 5. Race: Because systemic exposure to this medicine is increased in Asian patients, the recommended initial dose is 5 milligrams. Administration of the 40-milligram dose is contraindicated. 6. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 milligrams. Administration of the 40-milligram dose of this medicine is contraindicated in some of these patients. For patients taking valsartan and rosuvastatin concomitantly, they may switch to this medicine (a combination product with the same amount of each active ingredient) for convenience.
Child dose
Safety and efficacy have not been established in children and adolescents under 18 years of age. Safety and efficacy have not been established in children and adolescents under 18 years of age.

Ingredients

Manufacturer
Myeongmoon Pharmaceutical Co., Ltd.

Efficacy & effects

Treatment of hypertension and heart failure, improvement of dyslipidemia, and inhibition of atherosclerosis progression and cardiovascular risk

  • Essential hypertension
  • heart failure
  • heart failure intolerant to ACE inhibitors
  • left ventricular failure
  • left ventricular systolic dysfunction
  • primary hypercholesterolemia
  • heterozygous familial hypercholesterolemia
  • combined hyperlipidemia
  • homozygous familial hypercholesterolemia
  • hypercholesterolemia
  • primary dysbetalipoproteinemia
  • elevated high-sensitivity C-reactive protein
View approved original text

This medication is used for patients who require the combined administration of valsartan and rosuvastatin. Valsartan treats essential hypertension and heart failure, particularly in heart failure patients intolerant to ACE inhibitors, and helps reduce the risk of death after myocardial infarction. Rosuvastatin is used to treat hypercholesterolemia, combined hyperlipidemia, and familial hypercholesterolemia, and serves as an adjunct when dietary control is insufficient. Additionally, it improves health by reducing the risk of stroke, myocardial infarction, and arterial revascularization in patients at high risk for cardiovascular disease. This combination medication is used effectively to manage the health status of patients with concomitant hypertension and dyslipidemia.

How to take

Adult dose

This medicine is for use in adults only. The dosage should be individualized for each patient based on the efficacy and tolerability of the valsartan and rosuvastatin components. ◆ Valsartan 1. Essential hypertension Take with water during a meal or between meals. If possible, it is recommended to take the medicine at the same time each day (e.g., in the morning). 1) Adults: The recommended dose is 80 mg of valsartan orally once daily, regardless of sex or race. The blood pressure-lowering effect develops gradually within 2 weeks and reaches its maximum after 4 weeks. For patients whose blood pressure is not adequately controlled, the dose may be increased to 160 mg once daily or a diuretic may be administered concomitantly. If additional blood pressure reduction is needed, the dose may be increased to a maximum of 320 mg daily. 2) Older adults (75 years or older): Initiate treatment with 40 mg of this medicine once daily. 3) Patients with renal impairment: (1) Creatinine clearance 20 ∼ 50 mL/min: No dose adjustment is necessary. (2) Creatinine clearance 10 ∼ 20 mL/min: Initiate treatment with 40 mg of this medicine once daily. (3) Creatinine clearance below 10 mL/min and patients on dialysis: Do not administer this medicine. 4) Patients with intravascular volume depletion: For patients with intravascular volume depletion (e.g., patients taking high doses of diuretics whose dose cannot be reduced), initiate treatment with 40 mg of this medicine once daily. 5) Patients with hepatic impairment: In patients with mild or moderate hepatic impairment, initiate treatment with 40 mg of this medicine once daily; the dose should not exceed 80 mg daily. Do not administer this medicine to patients with severe hepatic impairment, cirrhosis, or cholestasis. 2. Heart failure Adults: The recommended initial dose is 40 mg of this medicine orally twice daily. The dose may be increased to 80 mg or 160 mg per dose. When administered concomitantly with a diuretic, consideration should be given to reducing the diuretic dose. The maximum daily dose is 320 mg, administered in divided doses. Triple combination therapy with this medicine, an ACE inhibitor, and a beta blocker is not recommended. 3. Reduction of the risk of death after myocardial infarction Adults: Treatment may be initiated within 12 hours after the onset of myocardial infarction. The recommended initial dose is 20 mg of this medicine twice daily, followed over several weeks by dose increases to 40 mg, 80 mg, and 160 mg per dose twice daily, taking the patient's tolerability into account. Consider dose reduction if symptoms of hypotension or renal failure occur. This medicine may also be administered to patients receiving other treatments after myocardial infarction (e.g., thrombolytic agents, acetylsalicylic acid, beta blockers, and statins). However, concomitant use with an ACE inhibitor is not recommended. 4. Patients with renal impairment: No dose adjustment is necessary when creatinine clearance is 10 mL/min or higher. However, this medicine should not be administered to patients with creatinine clearance below 10 mL/min or to patients on dialysis, as there is no experience with its use in these patients. 5. Patients with hepatic impairment: In patients with mild or moderate hepatic impairment, the daily dose of this medicine should preferably not exceed 80 mg. If administering 80 mg or more daily, consider whether the benefits of dose escalation outweigh the risks. Do not administer this medicine to patients with severe hepatic impairment, cirrhosis, or cholestasis. ◆ Rosuvastatin 1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with this medicine, and continue the diet throughout the treatment period. This medicine may be taken at any time of day, with or without food. The initial dose is 5 milligrams once daily. If a greater reduction in LDL cholesterol is needed, the dose may be adjusted to the maintenance dose. The maintenance dose is 10 milligrams once daily, which is sufficient for most patients. The maintenance dose should be adjusted appropriately at intervals of 4 weeks or longer according to LDL cholesterol levels, treatment goals, and patient response; it may be increased to a maximum of 20 milligrams daily. 2. Older adults: No dose adjustment is necessary. 3. Patients with renal impairment: No dose adjustment is necessary in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Particular caution is required when administering 20 mg of this medicine to patients with moderate renal impairment. 4. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or lower, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score above 9. Do not administer this medicine to patients with active liver disease. 5. Race: Because systemic exposure to this medicine is increased in Asian patients, the recommended initial dose is 5 milligrams. Administration of the 40-milligram dose is contraindicated. 6. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 milligrams. Administration of the 40-milligram dose of this medicine is contraindicated in some of these patients. For patients taking valsartan and rosuvastatin concomitantly, they may switch to this medicine (a combination product with the same amount of each active ingredient) for convenience.

Child dose

Safety and efficacy have not been established in children and adolescents under 18 years of age. Safety and efficacy have not been established in children and adolescents under 18 years of age.

Precautions

This medication can cause severe harm to the fetus when taken during pregnancy, especially in the second and third trimesters, so it should be discontinued immediately if pregnancy is confirmed. Patients with allergies to this medication, women of childbearing potential, those with severe liver or kidney disease, and patients with muscle disease should not take this medication. Elderly patients or those with elevated potassium levels in the blood, and patients with impaired liver function should be particularly cautious when taking this medication, and may sometimes need repeated liver function tests. Patients with heart valve disease or those at risk of sudden drops in blood pressure should also exercise caution when taking this medication. This medication can cause muscle pain or weakness, and rarely rhabdomyolysis, so if any abnormal symptoms in the muscles occur, consult a doctor immediately. This medication may interact with other drugs; therefore, caution is necessary, especially when taken with potassium-sparing diuretics, non-steroidal anti-inflammatory drugs, lithium, certain antibiotics or antifungals. Women who are pregnant or nursing should avoid taking this medication, and those who plan to conceive should consult a doctor and use appropriate contraception. The safety and effectiveness in children and adolescents have not been established; therefore, it should not be taken by individuals under 18 years of age. In case of overdose, blood pressure may drop suddenly, so seek medical attention immediately, and blood dialysis is not effective. This medication should be stored out of the reach of children, and transferring to another container should be avoided. During treatment, dizziness or drowsiness may occur, so caution is advised when driving or operating machinery.

Side effects

Dyspepsia, nausea, chest discomfort, dizziness, headache, conjunctival hemorrhage, constipation, weakness, chest pain, facial edema, peripheral edema, nasopharyngitis, urinary tract infection, contusion, increased serum hepatic amino transferases, increased serum creatine phosphokinase, increased serum potassium, increased gamma-glutamyl transferase, musculoskeletal stiffness, limb pain, sensory loss, anxiety, upper respiratory tract infection, edema, weakness, tension exacerbation, decreased motor function syndrome, confusion, rash, myalgia, viral infection, upper respiratory tract infection, cough, diarrhea, fatigue, rhinitis, sinusitis, abdominal pain, abdominal pain, pharyngitis, arthralgia, hypotension, orthostatic dizziness, orthostatic hypotension, renal function impairment, hyperkalemia, angioedema, vascular edema, erythema, itching, serum sickness, vasculitis, syncope, epistaxis, hepatitis, shock, loss of consciousness, rhabdomyolysis, agranulocytosis, leukopenia, thrombocytopenia, decreased red blood cell volume, decreased hemoglobin, polyneuropathy, memory loss, peripheral neuropathy, dyspnea, jaundice, Stevens-Johnson syndrome, hives, lupus-like syndrome, immune-mediated necrotizing myopathy, hematuria, depression, sleep disorders, interstitial lung disease, sexual dysfunction, gynecomastia, liver failure, cognitive impairment, myasthenia gravis, ocular myasthenia, headache, dizziness, constipation, nausea, abdominal pain, pancreatitis, pruritus, rash, myalgia, myopathy, rhabdomyolysis, weakness

Not everyone experiences these, and they can vary from person to person.

Storage

This medication is sensitive to light and should be stored in a special container that does not allow light in. Additionally, it should be kept at room temperature, between 1 to 30 degrees Celsius, as extreme hot or cold conditions can affect its efficacy.

Appearance and packaging

Appearance

Brown oval film-coated tablets

Package unit

30 tablets/box[(10 tablets/PTP)*3]

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.